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Background: Although record linkage of routinely collected health datasets is a valuable research resource, most
datasets are established for administrative purposes and not for health outcomes research. In order for meaningful
results to be extrapolated to specific populations, the limitations of the data and linkage methodology need to be
investigated and clarified. It is the objective of this study to investigate the differences in ascertainment which may
arise between a hospital admission dataset and a dispensing claims dataset, using major depression in pregnancy
as an example. The safe use of antidepressants in pregnancy is an ongoing issue for clinicians with around 10% of
pregnant women suffer from depression. As the birth admission will be the first admission to hospital during their
pregnancy for most women, their use of antidepressants, or their depressive condition, may not be revealed to the
attending hospital clinicians. This may result in adverse outcomes for the mother and infant.
Methods: Population-based de-identified data were provided from the Western Australian Data Linkage System
linking the administrative health records of women with a delivery to related records from the Midwives’
Notification System, the Hospital Morbidity Data System and the national Pharmaceutical Benefits Scheme dataset.
The women with depression during their pregnancy were ascertained in two ways: women with dispensing records
relating to dispensed antidepressant medicines with an WHO ATC code to the 3rd level, pharmacological subgroup,
‘N06A Antidepressants’; and, women with any hospital admission during pregnancy, including the birth admission,
if a comorbidity was recorded relating to depression.
Results: From 2002 to 2005, there were 96698 births in WA. At least one antidepressant was dispensed to 4485
(4.6%) pregnant women. There were 3010 (3.1%) women with a comorbidity related to depression recorded on
their delivery admission, or other admission to hospital during pregnancy. There were a total of 7495 pregnancies
identified by either set of records. Using data linkage, we determined that these records represented 6596
individual pregnancies. Only 899 pregnancies were found in both groups (13.6% of all cases). 80% of women
dispensed an antidepressant did not have depression recorded as a comorbidity on their hospital records. A simple
capture-recapture calculation suggests the prevalence of depression in this population of pregnant women to be
around 16%.
Conclusion: No single data source is likely to provide a complete health profile for an individual. For women with
depression in pregnancy and dispensed antidepressants, the hospital admission data do not adequately capture all cases.
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Data linkage of administrative data has been a rich re-
source for Western Australian researchers for a number of
years [1-5]. The more recent approval to link national data
from the Pharmaceutical Benefits Scheme (PBS) to
datasets in the Western Australian Data Linkage System
(WADLS) provides new and valuable opportunities to
examine birth outcome profiles of prescription medicines
dispensed for use during the preconception period and
pregnancy. However, most of the datasets were established
for administrative purposes and not for health outcomes
research. In order for meaningful results to be extrapo-
lated to specific populations, the limitations of the data
and linkage methodology need to be investigated and
clarified. An important step is to understand the limits of
case ascertainment within each dataset.
The Mental Health Services in Australia report uses
data from the National Survey of Mental Health and
Wellbeing 2007 (N = 8800 Australians aged 16–85
years), and from the National Mental Health Establish-
ments Database of the Australian Institute of Health and
Wellbeing [6]. In the foreword to the 2006–2007 report,
the director notes, “At this stage of data development,
the information we can provide is limited to the number
of services, or visits, or prescriptions delivered across
Australia. We still have very little information about the
number of people involved, or the services used per per-
son. This remains an important data gap that can only
be addressed by connecting information for mental
health consumers within and across various datasets.
This might be achieved by a range of strategies including
data linkage as well as the information that might flow
from the implementation of e-health” [7]. The report
showed the most common type of management reported
for mental health-related problems was a medication be-
ing prescribed, supplied or recommended by the general
practitioner. Antidepressants were the most common
medication, followed by anxiolytics, and hypnotics and
sedatives.
Depression is a major public health issue in Australia.
In 2009–10, more than 10% of all PBS prescription
claims were related to mental health conditions [8]. A
large Australian study found that around 9% of women
experienced depression in the antenatal period and 16%
in the postnatal period, [9] so depression, as an identi-
fied condition, should be well-represented in the admin-
istrative health datasets relating to pregnancy.
It is the objective of this study to investigate the differ-
ences in ascertainment between two datasets, using
major depression in pregnancy as an example.
Methods
This was a population-based data linkage study investi-
gating pregnancy events in WA from 2002 to 2005. Apregnancy event was defined as a hospital admission rec-
ord in the Hospital Morbidity Data System (HMDS)
with a diagnosis code between O00-O99, based upon
the International Statistical Classification of Diseases
and Related Health Problems, Tenth Revision, Australian
Modification (ICD-10-AM) [10]. De-identified data were
provided from the WADLS, linking the records of
women with each pregnancy event to any related records
in the HMDS, the Midwives’ Notification System
(MNS), and the Registry of Births and Deaths. These
datasets were linked to each other and to data from the
national PBS. The linkages and methodology have been
described previously [11,12].
With data linkage, we could overlay the dates of each
woman’s pregnancy from the MNS (based upon last men-
strual period and delivery date) to the PBS dispenses to
each woman within the same time frame, to determine ex-
posures to PBS medicines during pregnancy. Using these
dates we also determined the hospital admissions for each
woman that occurred during her pregnancy. There were
112 pregnancies without an MNS record and these were
excluded in the initial validation of the datasets.
In Australia, community prescriptions (i.e. non-public
hospital) are dispensed either as private prescriptions or
under one of two subsidisation schemes—the PBS and
the Repatriation Pharmaceutical Benefits Scheme. All
Australians are eligible to receive subsidised rates for
prescribed medicines approved under the PBS, with
around 80% of prescriptions dispensed in Australia being
subsidised. Patients are grouped into two classes: general
and concessional. As the general patient copayment
rises, the dispensed prices of many of the cheaper medi-
cations fall under this level. In such cases the patient
pays the full price and no claim for payment is made
under the PBS. For the year ending June 2006, 83.8% of
all dispenses and 80.0% of expenditure recorded on the
PBS were for concessional patients [13]. New medicines
are usually listed on the PBS at the full copayment
amount, and hence all dispenses are captured in the
data. However, the cost to the patient of older medicines
and generic versions tend to fall below the copayment
level and so not all medicines have been recorded previ-
ously for general patients.
Records from the PBS relating to antidepressant use
were ascertained by selecting those dispenses of medi-
cines with a WHO Anatomical Therapeutic Chemical
(ATC) code to the 3rd level, pharmacological subgroup,
‘N06A Antidepressants.’ Women with any dispense of a
medicine during her pregnancy that included one of
these codes were ascertained as a PBS case. The medi-
cines in this group are listed in Table 1. The copayment
amount for general patients for fluvoxamine maleate 50
mg tablets and moclobemide 150 mg tablets fell below
the subsidy level from April to December 2005 and from
Table 1 Ascertainment of pregnant women with depression from dispensing data, 2002-2005
Pregnancy
Risk Code
Dispenses PBS cases PBS, no HMDS PBS and HMDS
N % N % N % N %
Pharmaceutical Benefits Scheme 20879 100.0% 4485 100.0% 3586 80.0% 899 20.0%
Sertraline hydrochloride C 5536 26.5% 1340 29.9% 1082 30.2% 258 28.7%
Citalopram hydrobromide C 4784 22.9% 1136 25.3% 897 25.0% 239 26.6%
Paroxetine hydrochloride* C/D 3180 15.2% 676 15.1% 565 15.8% 111 12.3%
Venlafaxine hydrochloride B2 3146 15.1% 581 13.0% 430 12.0% 142 15.8%
Fluoxetine hydrochloride C 1509 7.2% 364 8.1% 280 7.8% 84 9.3%
Escitalopram oxalate C 775 3.7% 241 5.4% 189 5.3% 52 5.8%
Mirtazapine B3 510 2.4% 140 3.1% 85 2.4% 55 6.1%
Fluvoxamine maleate C 412 2.0% 140 3.1% 115 3.2% 25 2.8%
Amitriptyline hydrochlorine C 273 1.3% 105 2.3% 79 2.2% 26 2.9%
Dothiepin hydrochloride C 376 1.8% 78 1.7% 62 1.7% 16 1.8%
Moclobemide B3 92 0.4% 40 0.9% 34 0.9% 6 0.7%
Doxepine hydrochloride C 137 0.7% 32 0.7% 20 0.6% 12 1.3%
Reboxetine mesilate B1 89 0.4% 24 0.5% 16 0.4% 8 0.9%
Imipramine hydrochloride C 31 0.1% 8 0.2% 6 0.2% <5 0.2%
Mianserin hydrochloride B2 9 0.0% 6 0.1% <5 0.1% <5 0.2%
Nefazodone hydrochloride B3 14 0.1% 5 0.1% <5 0.1% <5 0.1%
Nortriptyline hydrochloride C 6 0.0% <5 0.1% <5 0.1% 0 0.0%
Pregnancy Risk Code: Australian category of risk for the medicine’s use in pregnancy.
* changed from category C to D, September 2005.
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20 mg tablets. Other forms of fluvoxamine maleate and
moclobemide were listed at the maximum copayment
level during this time. All other antidepressants were
listed at the maximum copayment level for the period of
the study. The PBS did not collect data on dispenses to
patients in public hospitals until December 2004. As de-
pression is a chronic condition, it is not likely that a
woman would be dispensed an antidepressant only once
and whilst she was in hospital.
The system used in Australia to categorise the risk of
drug use in pregnancy is a slightly modified version of the
Swedish categorisation (Farmaceutiska Specialiteter i Sve-
rige) and was adopted by the Australian Drug Evaluation
Committee (ADEC) in 1989 [14,15]. It includes most of
the commonly-used prescription and over-the-counter
medicines used in Australia. The categorisations apply
only to recommended therapeutic doses in women in the
reproductive age group. For pharmaceutical products
containing two or more active medicines, the categorisa-
tion of the combination is based on the component with
the most restrictive categorisation [15]. There are around
950 medicines listed in the ADEC classifications in preg-
nancy. The antidepressants were classified as B1, B2, B3, C
or D for risk for use in pregnancy.
The hospital admission data include a principal diag-
nosis and up to 20 comorbidities (‘additional diagnoses’)as recorded on the discharge records. The codes are
based upon ICD-10-AM [10]. According to the HMDS
coding guide that was current during the study, [16]
additional diagnoses with the following characteristics
need to be coded:
* require therapeutic treatment;
* require performance of a diagnostic procedure;
* increase nursing care and/or monitoring; or,
* may extend the length of stay in hospital.
‘A condition is not routinely coded just because a pa-
tient is on ongoing medication treatment of a condition.
However, if the medication is altered or adjusted during
the episode of care, the condition should be coded.’
We included any hospital admission during pregnancy as
well as the birth admission. The codes we used relating to
depression are listed in Table 2. These codes are the same
as those suggested in the Private Mental Health Alliance
[17] and the National Collaborating Centre for Mental
Health [18]. Women with any admission that included one
of these codes as a principal diagnosis or comorbidity in
the record were ascertained as an HMDS case.
The Australian Bureau of Statistics has released Socio-
Economic Indexes for Areas (SEIFA) based on the infor-
mation collected in the five-yearly Census of Population
and Housing. These indexes are widely used measures of
Table 2 Ascertainment of pregnant women with depression from admissions data, 2002–2005 by ICD-10 codes - 3010
HMDS cases
HMD cases HMDS, no PBS HMDS and PBS (AD) HMDS and PBS (not AD)
N % N % N % N %
Hospital Morbidity Data System* 3010 100.0% 978 32.5% 899 29.9% 1133 37.6%
0993 Mental disorders and diseases of the nervous system
complicating pregnancy, childbirth and the puerperium
2484 82.5% 791 80.9% 746 83.0% 947 83.6%
F32 Depressive episode 628 20.9% 112 11.5% 399 44.4% 117 10.3%
Z86.5 Personality history of other mental and behavioural
disorders
540 17.9% 190 19.4% 151 16.8% 199 17.6%
F33 Recurrent depressive disorder 157 5.2% 37 3.8% 65 7.2% 55 4.9%
F41.2 Mixed anxiety and depressive disorder 97 3.2% 24 2.5% 48 5.3% 25 2.2%
F31.9 Bipolar affective disorder, unspecified 48 1.6% 5 0.5% 27 3.0% 16 1.4%
F31.7 Bipolar affective disorder, currently in remission 9 0.3% <5 0.4% <5 0.1% <5 0.4%
F31.3 Bipolar affective disorder, current episode mild or
moderate depression
<5 0.1% 0 0.0% <5 0.2% <5 0.1%
F31.4 Bipolar affective disorder, current episode severe
depression without psychotic symptoms
<5 0.0% 0 0.0% <5 0.1% 0 0.0%
F31.6 Bipolar affective disorder, current episode mixed <5 0.0% 0 0.0% 0 0.0% <5 0.1%
F31.8 Other bipolar affective disorders <5 0.1% 0 0.0% <5 0.2% <5 0.2%
F31.5 Bipolar affective disorder, current episode severe
depression with psychotic symptoms
0 0.0% 0 0.0% 0 0.0% 0 0.0%
AD: antidepressant.
* totals do not equal the sum of the column as women may be diagnosed with more than one disorder or have more than one admission during their pregnancy.
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level. The indexes rank and identify areas that are rela-
tively more, or less, disadvantaged. They provide context-
ual information about the area in which a person lives.
The indexes have been obtained by principal components
analysis which summarises the information from a variety
of social and economic variables, calculating weights that
will give the best summary for the underlying variables.
The categories of variables include income, education, em-
ployment, occupation and housing [19].
Three distinct groups were identified: HMDS cases
only, PBS cases only, and cases in both datasets. Within
the HMDS cases only, two subsets were found: those
women dispensed PBS medicines other than antidepres-
sants, and women not dispensed any PBS medicines.
These two subsets of HMDS cases are important and we
wanted to distinguish between these HMDS groups. The
women who were not dispensed any PBS items may be a
healthier group; they may be women who had planned
their pregnancy and wished to avoid in utero exposure
to prescription medicines; or, they may have only used
medicines which were not captured by the PBS collec-
tion (for example: antibiotics dispensed to general
patients, complementary medicines, over the counter
medicines). Comparisons of demographic, pregnancy,
labour and delivery characteristics using MNS data were
also made between the women identified with depres-
sion using the PBS (any PBS cases) and the remainingwomen identified with depression using the hospital ad-
missions (HMDS only cases). Odds ratios with 95% con-
fidence intervals (OR; 95% CI) were calculated for all
comparisons of prevalence. Student’s t-tests were used
to compare the means of continuous measures such as
maternal age and gestation.
The WADLS uses the Automatch software package [20]
with probabilistic matching based upon medical record
number, surname, first given name and initial, date of
birth, sex and address as the principal matching fields.
Missed links have been estimated at 0.11% [21]. The
WADLS has been validated previously [21,22] and has
been used extensively for health research [23]. All records
for this study were also validated internally. For example,
sex and dates of birth or death were checked across each
source. The researchers received all data in a de-identified
form from the WADLS. The datasets were analysed using
SAS software, version 9.2 [24]. To fulfil the requirements
of ethics committees’ approvals relating to individual priv-
acy, we have not reported cell sizes with less than five
study subjects. This project has approval from the Human
Research Ethics Committees of The University of Western
Australia and the Department of Health WA.
Results
Based upon hospital admission records and midwives’
notifications, there were 96698 birth events in WA from
2002 to 2005.
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At least one antidepressant was dispensed to 4485
(4.6%) women having a birth event with a total of 20879
dispenses of 17 generic medicines (PBS cases): Table 1.
There were 38 different forms of antidepressant dis-
pensed with 24 (63%) dispensed to at least 10 pregnant
women. Nearly half of all dispenses of an antidepressant
were for sertraline hydrochloride (26.5%) or citalopram
hydrobromide (22.9%). During the period of this study,
96.1% of the dispenses of antidepressants under the PBS
to the pregnant women were as “Restricted Benefit” use
which means the medicine can only be prescribed for
specific therapeutic uses. These uses are listed in the
PBS as ‘major depressive disorders,’ ‘obsessive compul-
sive disorder,’ and ‘panic disorder where other treatments
have failed or are inappropriate.’ This means the women
being dispensed the antidepressants under the PBS were
confirmed by their clinician as having the need for the
therapeutic use required.
Ascertainment of cases from hospital admission records
(HMDS cases)
There were 108088 hospital admissions during preg-
nancy with 89% of the women having only one admis-
sion during their pregnancy and this admission was for
the delivery. There were 3010 (3.1%) women with a co-
morbidity related to depression recorded on their deliv-
ery admission, or other admission to hospital during
pregnancy (HMDS cases): Table 2. The most common
comorbidity codes recorded were ‘O99.3 mental disor-
ders and diseases of the nervous system complicating
pregnancy, childbirth and the puerperium’ (82.5%), ‘F32
depressive episode’ (20.9%) and ‘Z86.5 Personal history
of other mental and behavioural disorders’ (17.9%).
Comparison of ascertained cases by dataset
There were a total of 7495 pregnancies identified by either
set of records. Using data linkage, we could determine that
these cases represented 6596 individual pregnancies (6.8%
of 96698 pregnancies). There were 3586 pregnancies that
were PBS cases but not HMDS cases (54.4% of all cases)
and 2111 pregnancies that were HMDS cases and not PBS
cases (32.0% of all cases): Figure 1. Only 899 pregnancies
were found in both groups (13.6% of all cases). The areas of
the circles in the Venn diagram (Figure 1) are proportional
to the number of cases ascertained in each dataset. Using a
simple capture-recapture analysis, [25] the estimated total
number of cases of depression in the 96698 pregnant
women would be 15007 (95% CI: 14274–15741), i.e. 15.5%.
Other PBS medicines dispensed
Of the 2111 HMDS cases not dispensed an antidepres-
sant but with depression recorded in their hospital ad-
mission records, 978 were not dispensed any medicinesunder the PBS. The remaining 1133 were dispensed a
medicine under the PBS but not an antidepressant. The
most frequently dispensed medicines were amoxi-
cillin (N = 290, 25.8%), metoclopramide hydrochloride
(N = 200, 17.8%) and cephalexin (N = 198, 17.6%).
Other morbidities recorded for PBS cases
Of the 4485 cases with an antidepressant dispensed (PBS
cases), 899 had a comorbidity of depression recorded,
3481 had other comorbidities recorded that were not re-
lated to depression, and 105 did not have any comorbid-
ity recorded on their hospital admissions. The most
commonly recorded comorbidities for the 3481 cases are
listed in Table 3; with ‘Z72 Problems related to lifestyle’
(N = 727, 20.9%) and ‘O70 Perineal laceration during de-
livery’ (N = 718, 20.6%) being the most common.
Demographic, pregnancy and delivery characteristics
We investigated the demographic and pregnancy charac-
teristics using data recorded in the MNS: Table 4. We
compared the PBS cases (‘any PBS’ cases; N = 4485) with
the HMDS cases who were not ascertained in the PBS
(‘HMDS only’ cases; N = 2111).
In comparison to the women not dispensed an anti-
depressant but with a comorbidity record indicating de-
pression, the women dispensed an antidepressant were
less likely to have a preterm delivery (0.6; 0.5-0.7), and
four times more likely to be Caucasian (4.4; 3.7-5.2).
These women were more likely to have had a previous
pregnancy (1.3; 1.1-1.4) and a singleton birth (1.6; 1.1-
2.2). Their delivery was more likely to be attended by an
obstetrician (1.6; 1.4-1.8), more likely to be an elective
Caesarean (1.2; 1.1-1.4), and less likely to be an emer-
gency Caesarean (0.7; 0.6-0.8). They were more likely to
have a precipitate delivery (1.4; 1.1-1.8) and a local an-
aesthetic to the perineum (2.0; 1.5-2.6). They were less
likely to have their pregnancy complicated by pre-
eclampsia (0.6; 0.5-0.8); or to have smoked during their
pregnancy (0.8; 0.7-0.9).
Discussion
The objective of this study was to investigate the differ-
ences in ascertainment which may arise between a hos-
pital admission dataset and a dispensing claims dataset,
using major depression in pregnancy as an example.
Using data linkage, we found records for 6596 pregnan-
cies (6.8% all births) that indicated the mother was dis-
pensed an antidepressant during her pregnancy and/or
depression was recorded on her hospital admission re-
cords. This proportion is similar to a large Australian
study around the same period which reported 8.9%
women with an antenatal Edinburgh Postnatal Depres-
sion Scale >12 and 5.4% > 14 [9]. Only 899 pregnancies
were found in both groups (13.6% of all cases).
Figure 1 Ascertainment of cases by dataset, N = 6596 pregnancies.
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have depression recorded in their hospital records. 70%
of women with depression recorded in their hospital ad-
mission record were not dispensed an antidepressant. If
the true number of women with antenatal depression isTable 3 Most frequent comorbidities recorded on
hospital admissions, not related to depression, for the
4485 PBS cases
ICD category N %
HMDS comorbidity recorded as depression 899
no comorbidity recorded 105
HMDS comorbidity recorded, not related to depression 3481 100.0%
Z72 Problems related to lifestyle 727 20.9%
O70 Perineal laceration during delivery 718 20.6%
O34 Maternal care for known or suspected
abnormality of pelvic organs
608 17.5%
O99 Other maternal diseases classifiable elsewhere
but complicating pregnancy, childbirth and
the puerperium
583 16.7%
O68 Labour and delivery complicated by fetal stress
[distress]
487 14.0%
O80 Single spontaneous delivery 400 11.5%
O72 Postpartum haemorrhage 360 10.3%
O62 Abnormalities of forces of labour 341 9.8%
O92 Other disorders of breast and lactation
associated with childbirth
339 9.7%
O36 Maternal care for other known or suspected
fetal problems
288 8.3%
O32 Maternal care for known or suspected
malpresentation of fetus
276 7.9%
Z29 Need for other prophylactic measures 264 7.6%
O42 Premature rupture of membranes 262 7.5%
O69 Labour and delivery complicated by
umbilical cord complications
259 7.4%
O60 Preterm delivery 259 7.4%around 15% based upon the capture-recapture algorithm,
then there are many pregnant women with undiagnosed
or undeclared depression in the administrative health
datasets. These results are reflected in one of the state-
ments from the National beyondblue Perinatal Mental
Health program: depression and related difficulties affect
around 15 per cent of women during pregnancy and early
parenthood, and often goes undetected and untreated [9].
Not all women will continue taking antidepressants
whilst they are trying to become pregnant or once they
discover they are pregnant for fear of fetal harm. These
women may be part of the 978 women ascertained in
the HMDS without use of any PBS medicines. This
group of HMDS cases may also have been dispensed
medicines that are not routinely collected in the PBS.
The PBS dataset includes only medicines dispensed
under subsidy. Some medicines have a wide range of
forms of older medicines that are prescribed but no lon-
ger fully subsidised so the number of pregnant women
identified as treated would be under-estimated.
The women who were dispensed an antidepressant,
the PBS cases, were different in many ways from the
HMDS only group (Table 4). From the midwives’ data
we found these women were more likely to be Cauca-
sian, have already had at least one delivery, and to have
a singleton birth. They were more likely to have a higher
socio-economic status. Their delivery was less likely to
be preterm, to be induced, or to be an emergency Cae-
sarean section. They were less likely to have a pre-labour
rupture of membranes or experience a primary postpar-
tum haemorrhage of ≥ 500 ml. An obstetrician is more
likely to have attended the delivery, and more likely to
have an elective Caesarean. They were more likely to
have a precipitate delivery, and a local anaesthetic to
perineum. Many of these characteristics suggest a more
medically managed pregnancy and possibly better access
to medical services.
Table 4 Demographic and pregnancy, labour and delivery characteristics of all cases, using the midwives’ records
HMDS only Any PBS HMDS only
(N = 2111) (N = 4485) vs any PBS
N SD N SD t-test
Mean maternal age, yrs 29.0 6.1 30.1 5.8 <0.0001
Mean maternal height, cm 164.7 7.1 165.1 6.8 0.0244
Mean gestation, wks 37.7 3.3 38.2 2.3 <0.0001
Mean SEIFA 970.4 99.8 985.1 87.7 <0.0001
N % N % OR (95% CI)
Caucasian 1656 78.4 4217 94.0 0.23 (0.19-0.27)
Smoked during pregnancy 743 35.2 1312 29.3 1.32 (118–1.47)
Parity > 1 1584 75.0 3556 79.3 0.79 (0.70-0.89)
Singleton 2056 97.4 4410 98.3 0.64 (0.45-0.90)
Pregnancy characteristics
Preeclampsia 180 8.5 245 5.5 1.61 (1.32-1.97)
Gestational diabetes 97 4.6 210 4.7 0.98 (0.77-1.25)
Essential hypertension 25 1.2 69 1.5 0.77 (0.48-1.22)
Pre-existing diabetes 28 1.3 38 0.8 1.57 (0.96-2.57)
Other medical condition 1189 56.3 2251 50.2 0.78 (0.70-0.87)
CTG ante-partum 972 46.0 1615 36.0 0.66 (0.59-0.73)
CTG intra-partum 1024 48.5 1735 38.7 0.67 (0.60-0.74)
Labour and delivery characteristics
preterm 401 19.0 548 12.2 1.69 (1.46-1.94)
Induced labour 681 32.3 1307 29.1 1.16 (1.04-1.30)
Delivered by an obstetrician 552 26.1 1639 36.5 0.61 (0.55-0.69)
Precipitate delivery 93 4.4 273 6.1 0.71 (0.56-0.91)
Local anaesthetic to perineum 58 2.7 236 5.3 0.51 (0.38-0.68)
Elective Caesarean delivery 337 16.0 857 19.1 0.80 (0.70-0.92)
Emergency Caesarean delivery 408 19.3 663 14.8 1.38 (1.21-1.58)
Fetal distress 408 19.3 705 15.7 1.28 (1.12-1.47)
PPH (> = 500 mls) 468 22.2 508 11.3 2.23 (1.94-2.56)
Pre-labour rupture of membranes 193 9.1 260 5.8 1.64 (1.32-1.99)
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antidepressant but without depression recorded on their
hospital records (N = 3586/4485; 80%) is of concern. The
comorbidities coded for depression need not routinely
be coded just because a patient is on ongoing medica-
tion. However, if the medication is altered or adjusted
during the episode of care, or the patient requires add-
itional monitoring or nursing care, then the condition
should be coded [16]. Women with depression that is
well-controlled by medication or other therapies may
not inform the hospital clinicians of their depression for
a range of reasons; [26,27] or, the clinician may judge
that their depression did not require adjustment of
therapeutic treatment whilst she was admitted. In either
situation, the woman may not be recorded in the HMDS
as having depression. In primary health care settings, ifdepression is not routinely asked about, over 50% of
cases are missed, highlighting the need for a systematic
approach to perinatal psychosocial assessment [9,28]
and a similar situation may occur in the hospital setting.
Due to the amount of contact that women have with
health care providers during pregnancy, this is the best
time to start screening, [29] provided that adequately
trained staff are available to supply follow-up services to
those identified [30].
As more research into the effects of antidepressants
on the newborn is published, [31-35] it is hoped that
women will advise their hospital care-givers of their use
of antidepressants, particularly third trimester use, so
that withdrawal symptoms in the newborn may be man-
aged [36]. Since the time period of this study, the Na-
tional Perinatal Depression Initiative [37] has been
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provision of routine and universal screening for depres-
sion for women, once during pregnancy and again about
four to six weeks after the birth, by a range of health
care professionals including midwives, child and mater-
nal health nurses, general practitioners and Aboriginal
health workers – using the Edinburgh Postnatal Depres-
sion Scale [38].
No single data source is likely to provide a complete
health profile for an individual. For chronic conditions
in pregnancy treated with PBS medicines, the hospital
admission data do not adequately capture all cases. Data
linkage provides a rich resource at a relatively low cost
and in a timely manner, than other pregnancy studies in
pharmacovigilance whilst maintaining confidentiality.
There are several methodological limitations in the
current study. The main limitation of using dispensing
data relates to whether the medicine was consumed, or
consumed as directed, and we have no information in
this study for either of these aspects of use. However, by
reviewing the repeat dispenses of a medicine, adherence
may be inferred. In a previous study of SSRI dispensing
patterns, we found 75.4% of the women were dispensed
an SSRI in at least two consecutive trimesters, indicating
that the women were using the SSRIs [39].
At the time of this study, PBS prescription data was
only collected for prescriptions that attracted a Govern-
ment subsidy. Amendments to the Commonwealth of
Australia National Health Act 1953, enacted on 23 No-
vember 2010, require approved suppliers of Pharmaceut-
ical Benefits Scheme medicines to provide the Australian
Government, from 1 April 2012, with data on PBS pre-
scriptions that are priced below the general copayment
level (under copayment) [40]. The collection of under
copayment information will capture all dispenses of PBS
data, thus making the PBS dataset even more valuable
for health policy planning, monitoring risk, management
protocols, pharmacovigilance and monitoring the quality
use of medicines (including polypharmacy) in the
community.
Conclusions
A recent letter by Morton called for more rapid accumu-
lation of evidence regarding the safety of newer medica-
tions in pregnancy and lactation as clinicians currently
rely on the publication of case reports and case series by
single institutions [41]. Kelman et al. advocated the use
of data linkage of routinely collected health datasets in
Australia for pharmacovigilance in 2007 [42]. Properly
applied, automated databases can minimise the cost and
reduce the amount of time involved in obtaining infor-
mation on the effects of marketed medicines [43]. In
addition, they can be sufficiently large to study relatively
infrequently used medicines. Since medicine exposure isdetermined from pre-recorded automated data, there is
no opportunity for recall bias. Record linkage to a var-
iety of data sources provides the opportunity to control
for a wide range of potential confounders [44]. Other
major benefits include large sample sizes, generalizability
of results, and rapidity of analysis. The data can also be
used repeatedly to address a variety of hypotheses or
public health questions, and the studies are not intru-
sive. Data linkage provides a very cost-effective approach
to postmarketing surveillance and should provide more
timely signals of many adverse events in pregnancy than
the methods currently in place.
In order for meaningful results to be extrapolated to
specific populations, the limitations of the data and link-
age methodology need to be investigated and clarified.
This study highlights the limits of case ascertainment
within each dataset. It also raises concerns around the
reporting of depression in hospital records - whether
medical staff are aware that pregnant women are taking
antidepressants during their pregnancy, and the conse-
quences this may have for the neonate.
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